CN1741796A - 用于治疗泌尿疾病的减少剂量的托特罗定和其它抗毒蕈碱剂 - Google Patents

用于治疗泌尿疾病的减少剂量的托特罗定和其它抗毒蕈碱剂 Download PDF

Info

Publication number
CN1741796A
CN1741796A CNA2004800025658A CN200480002565A CN1741796A CN 1741796 A CN1741796 A CN 1741796A CN A2004800025658 A CNA2004800025658 A CN A2004800025658A CN 200480002565 A CN200480002565 A CN 200480002565A CN 1741796 A CN1741796 A CN 1741796A
Authority
CN
China
Prior art keywords
tolterodine
effective dose
muscarine antagonist
medicine effective
described application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800025658A
Other languages
English (en)
Chinese (zh)
Inventor
B·H·克比尔利
S·M·达尼霍尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pfizer Health AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32771960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1741796(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Health AB filed Critical Pfizer Health AB
Publication of CN1741796A publication Critical patent/CN1741796A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNA2004800025658A 2003-01-22 2004-01-14 用于治疗泌尿疾病的减少剂量的托特罗定和其它抗毒蕈碱剂 Pending CN1741796A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44169003P 2003-01-22 2003-01-22
US60/441,690 2003-01-22

Publications (1)

Publication Number Publication Date
CN1741796A true CN1741796A (zh) 2006-03-01

Family

ID=32771960

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800025658A Pending CN1741796A (zh) 2003-01-22 2004-01-14 用于治疗泌尿疾病的减少剂量的托特罗定和其它抗毒蕈碱剂

Country Status (17)

Country Link
US (2) US20060047007A1 (https=)
EP (1) EP1589958B2 (https=)
JP (1) JP2006515607A (https=)
KR (1) KR20050096147A (https=)
CN (1) CN1741796A (https=)
AT (1) ATE432070T1 (https=)
AU (1) AU2004206110A1 (https=)
BR (1) BRPI0406861A (https=)
CA (1) CA2514022C (https=)
DE (1) DE602004021233D1 (https=)
ES (1) ES2324712T5 (https=)
IL (1) IL169362A0 (https=)
MX (1) MXPA05007767A (https=)
PL (1) PL377995A1 (https=)
TW (1) TW200418447A (https=)
WO (1) WO2004064821A1 (https=)
ZA (1) ZA200505026B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004030931D1 (https=) * 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
ES2322148T3 (es) * 2004-08-11 2009-06-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
NZ570492A (en) * 2006-02-13 2011-08-26 Orient Pharma Samoa Co Ltd Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of excess salivation or drooling
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
WO2011109403A1 (en) * 2010-03-01 2011-09-09 Xenoport, Inc. Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
WO1998003067A1 (en) 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
DE69942928D1 (de) † 1998-08-27 2010-12-23 Pfizer Health Ab Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
HUP0203028A3 (en) * 1999-11-11 2005-07-28 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use

Also Published As

Publication number Publication date
JP2006515607A (ja) 2006-06-01
EP1589958B1 (en) 2009-05-27
KR20050096147A (ko) 2005-10-05
US20070155838A1 (en) 2007-07-05
CA2514022A1 (en) 2004-08-05
WO2004064821A1 (en) 2004-08-05
TW200418447A (en) 2004-10-01
CA2514022C (en) 2010-07-13
EP1589958A1 (en) 2005-11-02
BRPI0406861A (pt) 2006-01-03
ES2324712T3 (es) 2009-08-13
ATE432070T1 (de) 2009-06-15
US20060047007A1 (en) 2006-03-02
IL169362A0 (en) 2007-07-04
EP1589958B2 (en) 2012-04-11
ZA200505026B (en) 2006-07-26
MXPA05007767A (es) 2006-01-31
AU2004206110A1 (en) 2004-08-05
PL377995A1 (pl) 2006-02-20
ES2324712T5 (es) 2012-06-08
DE602004021233D1 (de) 2009-07-09

Similar Documents

Publication Publication Date Title
JP2019131598A (ja) タペンタドールの用量調節
AU2016371598B2 (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
AU2011235863A1 (en) Methods of improving quality of sleep
EP1572181A2 (de) Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor und deren verwendung zur behandlung von blasenfunktionsstoerungen
CN1211081C (zh) 坦洛新在制备神经原性膀胱伴有的排尿障碍治疗剂上的应用
WO2004084880A1 (en) METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
US20070155838A1 (en) New Method for Treating Urinary Disorders
CN1543344A (zh) 治疗尿失禁的芳基(或杂芳基)氮杂茂甲醇衍生物
JPH04300824A (ja) 尿失禁治療剤
EP1682110A1 (de) Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem alpha agonisten
JP7549405B2 (ja) 鎮痛・鎮痒医薬組成物及びその使用方法
HK1084028A (en) Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
TW200812579A (en) Treatment of pain
KR20070087643A (ko) Ｄ-트레오 메틸페니데이트를 이용한 치료
Neil et al. Successful use of Memantine in the treatment of severe phantom limb pain: case report and literature review
Biller et al. Overactive bladder: Pharmacologic therapy
CN1905865A (zh) 治疗肥胖的组合物药物疗法
WO2019167004A1 (en) Pharmaceutical formulation for the use in the treatment of depressive and anxiety disorders
Majmudar et al. Current drug treatments for female urinary incontinence
Bankhead Oral agent shows durable improvement in SUI patients.
CN1931153A (zh) 用于治疗抑郁症及相关病症的包括文拉法辛的药物组合物
Bankhead Existing anticholinergics show few CNS effects.
CN1223575A (zh) 用(s)－奥昔布宁和(s)－去乙基奥昔布宁治疗尿失禁
JPWO2006054514A1 (ja) 神経因性疼痛の予防又は治療用医薬組成物
WO2004084881A1 (en) METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1084028

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20060301

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1084028

Country of ref document: HK